Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that its key imaging study evaluating a novel approach to tracking multiple sclerosis (MS) has reached the halfway point in patient enrollment, with early results showing a meaningful signal in MS lesions. The milestone was reported as part of the company's ongoing imaging collaboration with Massachusetts General Hospital, where researchers are evaluating a novel positron emission tomography (PET) imaging tracer that could support the development of Lucid-MS, the company's MS drug candidate.
Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Approximately 2.9 million people are living with the disease globally, and nearly one million of those individuals are in the United States. Most people are diagnosed between the ages of 20 and 40, meaning MS strikes during some of the most productive years of a person's life.
The study is evaluating a technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent. This differentiation is crucial for developing effective treatments and monitoring disease progression. The preliminary imaging data is encouraging, according to the company, and supports the potential of the imaging tracer in clinical trials.
Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative and metabolic disorders. The company's stock trades on the NASDAQ under the symbol QNTM and on the Canadian Securities Exchange under the same symbol. For more information, visit the company's newsroom at https://nnw.fm/QNTM.
This development is important because it brings hope to millions affected by MS, a disease that currently has no cure. The ability to distinguish between reversible and permanent nerve damage could revolutionize how MS is treated, potentially allowing for earlier and more targeted interventions. The imaging tracer may also accelerate the development of Lucid-MS by providing a reliable biomarker for clinical trials.
NetworkNewsWire (NNW) is a specialized communications platform with a focus on financial news and content distribution. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, please visit https://www.NetworkNewsWire.com.
